Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?

British Journal of Pharmacology

Volumn 174, Issue 21, 2017, Pages 3749-3765

  Sala, Luca ^a   Bellin, Milena ^a   Mummery, Christine L ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

CARDIAC MUSCLE CELL; CARDIOTOXICITY; CELL DAMAGE; COMPUTER MODEL; DRUG SCREENING; ELECTROPHYSIOLOGICAL ASSAY; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SCREENING TEST; ANIMAL; CHEMICALLY INDUCED; CYTOLOGY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECT; ELECTROPHYSIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOTOXICITY; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGICAL PHENOMENA; HUMANS; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS;

EID: 84988358048     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13577     Document Type: Review

References (181)

1. Ahrens-Nicklas RC, Christini DJ (2009). Anthropomorphizing the mouse cardiac action potential via a novel dynamic clamp method. Biophys J 97: 2684–2692.
2. Akar JG, Akar FG (2006). Mapping arrhythmias in the failing heart: from Langendorff to patient. J Electrocardiol 39: S19–S23.
3. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010). Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102: 14–25.
4. Alexander SP, Catterall WA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: voltage-gated ion channels. Br J Pharmacol 172: 5904–5941.
5. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: transporters. Br J Pharmacol 172: 6110–6202.
6. Altomare C, Bartolucci C, Sala L, Bernardi J, Mostacciuolo G, Rocchetti M et al. (2015). IKr impact on repolarization and its variability assessed by dynamic clamp. Circ Arrhythm Electrophysiol 8: 1265–1275.
7. Amin AS, Wilde AAM (2016). Genetic screening in acquired long QT syndrome? Caution: proceed carefully. Eur Heart J 37: 1465–1468.
8. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60: 1789–1792.
9. Avior Y, Sagi I, Benvenisty N (2016). Pluripotent stem cells in disease modelling and drug discovery. Nat Rev Mol Cell Biol 17: 170–182.
10. Beauchamp P, Moritz W, Kelm JM, Ullrich ND, Agarkova I, Anson BD et al. (2015). Development and characterization of a scaffold-free 3D spheroid model of induced pluripotent stem cell-derived human cardiomyocytes. Tissue Eng Part C Methods 21: 852–861.
11. Bedut S, Seminatore Nole C, Lamamy V, Caignard S, Boutin JA, Nosjean O et al. (2016). High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes. Am J Physiol Heart Circ Physiol 311: H44–H53.
12. Bellin M, Mummery CL (2016). Stem cells: the cancer's gone, but did chemotherapy damage your heart? Nat Rev Cardiol 13: 383–384.
13. Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D et al. (2013). Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J 32: 3161–3175.
14. Bellin M, Marchetto MC, Gage FH, Mummery CL (2012). Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol 13: 713–726.
15. Bentzen BH, Bahrke S, Wu K, Larsen AP, Odening KE, Franke G et al. (2011). Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits. J Cardiovasc Pharmacol 57: 223–230.
16. Berger RD (2003). QT variability. J Electrocardiol 36 (Suppl.): 83–87.
17. Bhattacharya S, Burridge PW, Kropp EM, Chuppa SL, Kwok W-M, Wu JC et al. (2014). High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry. J Vis Exp : 52010. doi:10.3791/52010.
18. Birket MJ, Ribeiro MC, Kosmidis G, Ward D, Leitoguinho AR, van de Pol V et al. (2015). Contractile defect caused by mutation in MYBPC3 revealed under conditions optimized for human PSC-cardiomyocyte function. Cell Rep 13: 733–745.
19. Bizy A, Guerrero-Serna G, Hu B, Ponce-Balbuena D, Willis BC, Zarzoso M et al. (2013). Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes. Stem Cell Res 11: 1335–1347.
20. Bunnage ME (2011). Getting pharmaceutical R&D back on target. Nat Chem Biol 7: 335–339.
21. Burridge PW, Li YF, Matsa E, Wu H, Ong S-G, Sharma A et al. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med 22: 547–556.
22. Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD et al. (2014). Chemically defined generation of human cardiomyocytes. Nat Methods 11: 855–860.
23. Burridge PW, Sharma A, Wu JC (2015). Genetic and epigenetic regulation of human cardiac reprogramming and differentiation in regenerative medicine. Annu Rev Genet 49: 461–484.
24. Burridge PW, Thompson S, Millrod MA, Weinberg S, Yuan X, Peters A et al. (2011). A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 6: e18293.
25. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131: 1981–1988.
26. Cavallari LH (2012). Tailoring drug therapy based on genotype. J Pharm Pract 25: 413–416.
27. Cavero I, Guillon J-M, Ballet V, Clements M, Gerbeau J-F, Holzgrefe H (2016). Comprehensive in vitro proarrhythmia assay (CiPA): pending issues for successful validation and implementation. J Pharmacol Toxicol Methods. doi:10.1016/j.vascn.2016.05.012.
28. Chan Y-C, Ting S, Lee Y-K, Ng K-M, Zhang J, Chen Z et al. (2013). Electrical stimulation promotes maturation of cardiomyocytes derived from human embryonic stem cells. J Cardiovasc Transl Res 6: 989–999.
29. Chang Liao M-L, de Boer TP, Mutoh H, Raad N, Richter C, Wagner E et al. (2015). Sensing cardiac electrical activity with a cardiac myocyte – targeted optogenetic voltage indicator. Circ Res 117: 401–412.
30. Chen A, Ting S, Seow J, Reuveny S, Oh S (2014). Considerations in designing systems for large scale production of human cardiomyocytes from pluripotent stem cells. Stem Cell Res Ther 5: 12.
31. Chen IY, Matsa E, Wu JC (2016). Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol 13: 333–349.
32. Clements M (2016). Multielectrode array (mea) assay for profiling electrophysiological drug effects in human stem cell-derived cardiomyocytes. Curr Protoc Toxicol 68: 22.4.1–22.4.32.
33. Collins FS, Varmus H (2015). A new initiative on precision medicine. N Engl J Med 372: 793–795.
34. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G et al. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13: 419–431.
35. Cross MJ, Berridge BR, Clements PJM, Cove-Smith L, Force TL, Hoffmann P et al. (2015). Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. Br J Pharmacol 172: 957–974.
36. Crumb WJ, Vicente J, Johannesen L, Strauss DG (2016). An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J Pharmacol Toxicol Methods. doi:10.1016/j.vascn.2016.03.009.
37. Cuchiara ML, Olive JK, Matthews K (2015). Regulating the therapeutic translation of regenerative medicine. Expert Opin Biol Ther 15: 1387–1390.
38. Davis RP, Casini S, van den Berg CW, Hoekstra M, Remme CA, Dambrot C et al. (2012). Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125: 3079–3091.
39. de Villiers CP, van der Merwe L, Crotti L, Goosen A, George AL, Schwartz PJ et al. (2014). AKAP9 is a genetic modifier of congenital long-QT syndrome type 1. Circ Cardiovasc Genet 7: 599–606.
40. Dempsey GT, Chaudhary KW, Atwater N, Nguyen C, Brown BS, McNeish JD et al. (2016). Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging. J Pharmacol Toxicol Methods. doi:10.1016/j.vascn.2016.05.003.
41. Denning C, Borgdorff V, Crutchley J, Firth KSA, George V, Kalra S et al. (2016). Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform. Biochim Biophys Acta 1863: 1728–1748.
42. Devalla HD, Schwach V, Ford JW, Milnes JT, El-Haou S, Jackson C et al. (2015). Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. EMBO Mol Med 7: 394–410.
43. Di Pasquale E, Lodola F, Miragoli M, Denegri M, Avelino-Cruz JE, Buonocore M et al. (2013). CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis 4: e843.
44. Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermott JS et al. (2004). The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering [K+]o. J Pharmacol Toxicol Methods 50: 187–199.
45. Duchatelet S, Crotti L, Peat RA, Denjoy I, Itoh H, Berthet M et al. (2013). Identification of a KCNQ1 polymorphism acting as a protective modifier against arrhythmic risk in long-QT syndrome. Circ Cardiovasc Genet 6: 354–361.
46. Eder A, Vollert I, Hansen A, Eschenhagen T (2016). Human engineered heart tissue as a model system for drug testing. Adv Drug Deliv Rev 96: 214–224.
47. Ewer MS, Ewer SM (2015). Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12: 547–558.
48. Feinberg AW, Alford PW, Jin H, Ripplinger CM, Werdich AA, Sheehy SP et al. (2012). Controlling the contractile strength of engineered cardiac muscle by hierarchal tissue architecture. Biomaterials 33: 5732–5741.
49. Fendyur A, Spira ME (2012). Toward on-chip, in-cell recordings from cultured cardiomyocytes by arrays of gold mushroom-shaped microelectrodes. Front Neuroeng 5: 21.
50. Fermini B, Hancox JC, Abi-Gerges N, Bridgland-Taylor M, Chaudhary KW, Colatsky T et al. (2015). A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J Biomol Screen 21: 1–11.
51. Food and Drug Administration (2013). Paving the Way for Personalized Medicine: 1–62.
52. Friedrichs GS, Patmore L, Bass A (2005). Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods 52: 6–11.
53. Gibson JK, Yue Y, Bronson J, Palmer C, Numann R (2014a). Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents. J Pharmacol Toxicol Methods 70: 255–267.
54. Gibson K, Yue Y, Li P (2014b), Evaluation of drug mediated changes in action potentials recorded from adult human stem cell-derived Cor.4 U® cardiomyocytes.
55. Gibson K, Yue Y, Li P (2014c). Evaluation of drug mediated changes in action potentials recorded from adult human stem cell-derived iCell® cardiomyocytes.
56. Gintant G, Sager PT, Stockbridge N (2016). Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov 15: 457–471.
57. Hancox JC, McPate MJ, El Harchi A, Zhang YH (2008). The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 119: 118–132.
58. Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci 134: 412–426.
59. Hartjes KA, Li X, Martinez-Fernandez A, Roemmich AJ, Larsen BT, Terzic A et al. (2014). Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity. Stem Cells 32: 2350–2359.
60. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014). Clinical development success rates for investigational drugs. Nat Biotechnol 32: 40–51.
61. Hayakawa T, Kunihiro T, Ando T, Kobayashi S, Matsui E, Yada H et al. (2014). Image-based evaluation of contraction–relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: correlation and complementarity with extracellular electrophysiology. J Mol Cell Cardiol 77: 178–191.
62. Herron TJ, Lee P, Jalife J (2012). Optical imaging of voltage and calcium in cardiac cells & tissues. Circ Res 110: 609–623.
63. Himmel HM (2013). Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds. J Pharmacol Toxicol Methods 68: 97–111.
64. Hirt MN, Boeddinghaus J, Mitchell A, Schaaf S, Börnchen C, Müller C et al. (2014). Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. J Mol Cell Cardiol 74: 151–161.
65. Hochbaum DR, Zhao Y, Farhi SL, Klapoetke N, Werley CA, Kapoor V et al. (2014). All-optical electrophysiology in mammalian neurons using engineered microbial rhodopsins. Nat Methods 11: 825–833.
66. Hoekstra M, Mummery CL, Wilde AAM, Bezzina CR, Verkerk AO (2012). Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol 3: 346.
67. Huebsch N, Loskill P, Mandegar MA, Marks NC, Sheehan AS, Ma Z et al. (2015). Automated video-based analysis of contractility and calcium flux in human-induced pluripotent stem cell-derived cardiomyocytes cultured over different spatial scales. Tissue Eng Part C Methods 21: 467–479.
68. Hwang HS, Kryshtal DO, Feaster TK, Sanchez-Freire V, Zhang J, Kamp TJ et al. (2015a). Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. J Mol Cell Cardiol 85: 79–88.
69. Hwang HS, Kryshtal DO, Feaster TK, Sanchez-Freire V, Zhang J, Kamp TJ et al. (2015b). Human induced pluripotent stem cell (hiPSC) derived cardiomyocytes to understand and test cardiac calcium handling: a glass half full. J Mol Cell Cardiol 89: 379–380.
70. ICH (2005a). ICH E14 guidance for industry. Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (Center for Drug Evaluation and Research).
71. ICH (2005b) The non-clinical evaluation of the potential for delayed ventricular repolarization (Qt Interval Prolongation) by human pharmaceuticals. S7B Guideline.
72. Itoh H, Crotti L, Aiba T, Spazzolini C, Denjoy I, Fressart V et al. (2016). The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J 37: 1456–1464.
73. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A et al. (2011). Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471: 225–229.
74. Johnson JN, Ackerman MJ (2009). QTc: how long is too long? Br J Sports Med 43: 657–662.
75. Jones AR, Edwards DH, Cummins MJ, Williams AJ, George CH (2015). A systemized approach to investigate Ca(2+) synchronization in clusters of human induced pluripotent stem-cell derived cardiomyocytes. Front Cell Dev Biol 3: 89.
76. Kaestner L, Scholz A, Tian Q, Ruppenthal S, Tabellion W, Wiesen K et al. (2014). Genetically encoded Ca2+ indicators in cardiac myocytes. Circ Res 114: 1623–1639.
77. Kane C, Terracciano CM (2015). Induced pluripotent stem cell-derived cardiac myocytes to understand and test calcium handling: pie in the sky? J Mol Cell Cardiol 89: 376–378.
78. Kaneko T, Nomura F, Hattori A (2012). Improvement of electrical stimulation protocol for simultaneous measurement of extracellular potential with on-chip multi-electrode array system. Jpn J of Appl Phys 51: 06FK02.
79. Kijlstra JD, Hu D, Mittal N, Kausel E, van der Meer P, Garakani A et al. (2015). Integrated analysis of contractile kinetics, force generation, and electrical activity in single human stem cell-derived cardiomyocytes. Stem Cell Rep 5: 1226–1238.
80. Kim JJ, Yang L, Lin B, Zhu X, Sun B, Kaplan AD et al. (2015). Mechanism of automaticity in cardiomyocytes derived from human induced pluripotent stem cells. J Mol Cell Cardiol 81C: 81–93.
81. Kitaguchi T, Moriyama Y, Taniguchi T, Ojima A, Ando H, Uda T et al. (2016). CSAHi study: evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia – effects of 7 reference compounds at 10 facilities. J Pharmacol Toxicol Methods 78: 93–102.
82. Klimas A, Ambrosi CM, Yu J, Williams JC, Bien H, Entcheva E (2016). OptoDyCE as an automated system for high-throughput all-optical dynamic cardiac electrophysiology. Nat Commun 7: 1–12.
83. Koeppel F, Labarre D, Zitoun P (2012). Quickly finding a needle in a haystack: a new automated cardiac arrhythmia detection software for preclinical studies. J Pharmacol Toxicol Methods 66: 92–97.
84. Kola I, Landis J (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711–716.
85. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS et al. (2013). MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci Rep 3: 2100.
86. Kuusela J, Kujala VJ, Kiviaho A, Ojala M, Swan H, Kontula K et al. (2016). Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytes. Springerplus 5: 234.
87. Kyttälä A, Moraghebi R, Valensisi C, Kettunen J, Andrus C, Pasumarthy KK et al. (2016). Genetic variability overrides the impact of parental cell type and determines iPSC differentiation potential. Stem Cell Rep 6: 200–212.
88. Laverty HG, Benson C, Cartwright EJ, Cross MJ, Garland C, Hammond T et al. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 163: 675–693.
89. Leha A, Moens N, Meleckyte R, Culley OJ, Gervasio MK, Kerz M et al. (2016). A high-content platform to characterise human induced pluripotent stem cell lines. Methods 96: 85–96.
90. Li X, Zhang R, Zhao B, Lossin C, Cao Z (2016). Cardiotoxicity screening: a review of rapid-throughput in vitro approaches. Arch Toxicol 90: 1803–1816.
91. Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y et al. (2013). Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127: 1677–1691.
92. Lu HR, Whittaker R, Price JH, Vega R, Pfeiffer ER, Cerignoli F et al. (2015). High throughput measurement of Ca++ dynamics in human stem cell-derived cardiomyocytes by kinetic image cytometery: a cardiac risk assessment characterization using a large panel of cardioactive and inactive compounds. Toxicol Sci 148: 503–516.
93. Lu J, Wei H, Wu J, Jamil MFA, Tan ML, Adenan MI et al. (2014). Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PLoS One 9: e115648.
94. Ma D, Wei H, Lu J, Huang D, Liu Z, Loh LJ et al. (2015). Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther 6: 39.
95. Ma D, Wei H, Zhao Y, Lu J, Li G, Sahib NBE et al. (2013). Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int J Cardiol 168: 5277–5286.
96. Maddah M, Heidmann JD, Mandegar MA, Walker CD, Bolouki S, Conklin BR et al. (2015). A non-invasive platform for functional characterization of stem-cell-derived cardiomyocytes with applications in cardiotoxicity testing. Stem Cell Rep 4: 621–631.
97. Maillet A, Tan K, Chai X, Sadananda SN, Mehta A, Ooi J et al. (2016). Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Sci Rep 6: 25333.
98. Malan D, Zhang M, Stallmeyer B, Müller J, Fleischmann BK, Schulze-Bahr E et al. (2016). Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction. Basic Res Cardiol 111: 14–11.
99. Martignoni M, Groothuis GMM, de Kanter R (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2: 875–894.
100. Martiniano SL, Sagel SD, Zemanick ET (2016). Cystic fibrosis: a model system for precision medicine. Curr Opin Pediatr 28: 312–317.
101. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A et al. (2011). Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 32: 952–962.
102. McNaughton R, Huet G, Shakir S (2014). An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open 4: e004221–e004221.
103. McNeish J, Gardner JP, Wainger BJ, Woolf CJ, Eggan K (2015). From dish to bedside: lessons learned while translating findings from a stem cell model of disease to a clinical trial. Cell Stem Cell 17: 8–10.
104. Mehta A, Sequiera GL, Ramachandra CJA, Sudibyo Y, Chung Y, Sheng J et al. (2014). Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovasc Res 102: 497–506.
105. Meijer van Putten RME, Mengarelli I, Guan K, Zegers JG, van Ginneken ACG, Verkerk AO et al. (2015). Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1. Front Physiol 6: 7.
106. Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P, Agnetti G et al. (2016). Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail 22: 449–458.
107. Milan DJ, MacRae CA (2005). Animal models for arrhythmias. Cardiovasc Res 67: 426–437.
108. Mitcheson JS, Hancox JC, Levi AJ (1998). Cultured adult cardiac myocytes: future applications, culture methods, morphological and electrophysiological properties. Cardiovasc Res 39: 280–300.
109. Miyamoto T, Furusawa C, Kaneko K (2015). Pluripotency, differentiation, and reprogramming: a gene expression dynamics model with epigenetic feedback regulation. PLoS Comput Biol 11: e1004476.
110. Mosadegh B, Dabiri BE, Lockett MR, Derda R, Campbell P, Parker KK et al. (2014). Three-dimensional paper-based model for cardiac ischemia. Adv Healthc Mater 3: 1036–1043.
111. Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ. (2012). Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111: 344–358.
112. Musunuru K (2015). Personalized genomes and cardiovascular disease. Cold Spring Harb Perspect Med 5: a014068–a014068.
113. Natarajan A, Stancescu M, Dhir V, Armstrong C, Sommerhage F, Hickman JJ et al. (2011). Patterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform. Biomaterials 32: 4267–4274.
114. Nebert DW, Vesell ES (2006). Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol Sci 27: 580–586.
115. Nerbonne JM (2004). Studying cardiac arrhythmias in the mouse – a reasonable model for probing mechanisms? Trends Cardiovasc Med 14: 83–93.
116. Nozaki Y, Honda Y, Tsujimoto S, Watanabe H, Kunimatsu T, Funabashi H (2014). Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. Toxicol Appl Pharmacol 278: 72–77.
117. Nunes SS, Miklas JW, Liu J, Aschar-Sobbi R, Xiao Y, Zhang B et al. (2013). Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods 10: 781–787.
118. Obergrussberger A, Juhasz K, Thomas U, Stölzle-Feix S, Becker N, Dörr L et al. (2016). Safety pharmacology studies using EFP and impedance. J Pharmacol Toxicol Methods. doi:10.1016/j.vascn.2016.04.006.
119. O'Hara T, Rudy Y (2012). Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. Am J Physiol Heart Circ Physiol 302: H1023–H1030.
120. O'Hara T, Virág L, Varró A, Rudy Y (2011). Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 7: e1002061.
121. Onakpoya IJ, Heneghan CJ, Aronson JK (2016). Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit Rev Toxicol 46: 477–489.
122. Paci M, Hyttinen J, Aalto-Setälä K, Severi S (2013). Computational models of ventricular- and atrial-like human induced pluripotent stem cell derived cardiomyocytes. Ann Biomed Eng 41: 2334–2348.
123. Paci M, Hyttinen J, Rodriguez B, Severi S (2015). Human induced pluripotent stem cell-derived versus adult cardiomyocytes: an in silico electrophysiological study on effects of ionic current block. Br J Pharmacol 172: 5147–5160.
124. Paci M, Sartiani L, Del Lungo M, Jaconi M, Mugelli A, Cerbai E et al. (2012). Mathematical modelling of the action potential of human embryonic stem cell derived cardiomyocytes. Biomed Eng Online 11: 61.
125. Park SA, Lee S-R, Tung L, Yue DT (2014). Optical mapping of optogenetically shaped cardiac action potentials. Sci Rep 4: 6125–6110.
126. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203–214.
127. Paull D, Sevilla A, Zhou H, Hahn AK, Kim H, Napolitano C et al. (2015). Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods 12: 885–892.
128. Pekkanen-Mattila M, Kerkelä E, Tanskanen JMA, Pietilä M, Pelto-Huikko M, Hyttinen J et al. (2009). Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions – a comparison of multiple cell lines. Ann Med 41: 360–370.
129. Penttinen K, Swan H, Vanninen S, Paavola J, Lahtinen AM, Kontula K et al. (2015). Correction: antiarrhythmic effects of dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using iPSC models. PLoS One 10: e0134746.
130. Perry M (2005). Drug binding interactions in the inner cavity of hERG channels: molecular insights from structure–activity relationships of clofilium and ibutilide analogs. Mol Pharmacol 69: 509–519.
131. Priori SG (1998). Gene specific therapy for cardiac disease: the case of long QT syndrome. Rev Port Cardiol 17 (Suppl 3): III27–III38.
132. Pueyo E, Dangerfield CE, Britton OJ, Virág L, Kistamás K, Szentandrássy N et al. (2016). Experimentally-based computational investigation into beat-to-beat variability in ventricular repolarization and its response to ionic current inhibition. PLoS One 11: e0151461.
133. Raphael R, Purushotham D, Gastonguay C, Chesnik MA, Kwok W-M, Wu H-E et al. (2016). Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction. J Transl Med 14: 18.
134. Rast G, Weber J, Disch C, Schuck E, Ittrich C, Guth BD (2015). An integrated platform for simultaneous multi-well field potential recording and Fura-2-based calcium transient ratiometry in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes. J Pharmacol Toxicol Methods 75: 91–100.
135. Ravenscroft SM, Pointon A, Williams AW, Cross MJ, Sidaway JE (2016). Cardiac non-myocyte cells show enhanced pharmacological function suggestive of contractile maturity in stem cell derived cardiomyocyte microtissues. Toxicol Sci 152: 99–112.
136. Redfern WS, Carlsson L, Davis AS, Lynch WG, Mackenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32–45.
137. Ribeiro AJS, Ang Y-S, Fu J-D, Rivas RN, Mohamed TMA, Higgs GC et al. (2015a). Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc Natl Acad Sci U S A 112: 12705–12710.
138. Ribeiro MC, Tertoolen LG, Guadix JA, Bellin M, Kosmidis G, D'Aniello C et al. (2015b). Functional maturation of human pluripotent stem cell derived cardiomyocytes in vitro – correlation between contraction force and electrophysiology. Biomaterials 51: 138–150.
139. Robertson C, Tran DD, George SC (2013). Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells 31: 829–837.
140. Roden DM, George AL (2002). The genetic basis of variability in drug responses. Nat Rev Drug Discov 1: 37–44.
141. Rodin S, Antonsson L, Hovatta O, Tryggvason K (2014). Monolayer culturing and cloning of human pluripotent stem cells on laminin-521–based matrices under xeno-free and chemically defined conditions. Nat Protoc 9: 2354–2368.
142. Rodríguez B, Carusi A, Abi Gerges N, Ariga R, Britton O, Bub G et al. (2015). Human-based approaches to pharmacology and cardiology: an interdisciplinary and intersectorial workshop. Europace euv320.
143. Rubinstein E, Camm J (2002). Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 49: 593–596.
144. Sala L, Yu Z, Ward-van Oostwaard D, van Veldhoven JPD, Moretti A, Laugwitz K-L et al. (2016). A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. EMBO Mol Med. doi: 10.15252/emmm.201606260.
145. Sander JD, Joung JK (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32: 347–355.
146. Sanguinetti MC, Tristani-Firouzi M (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463–469.
147. Šarić T, Halbach M, Khalil M, Er F (2014). Induced pluripotent stem cells as cardiac arrhythmic in vitro models and the impact for drug discovery. Expert Opin Drug Discovery 9: 55–76.
148. Scheel O, Frech S, Amuzescu B, Eisfeld J, Lin KH, Knott T (2014). Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology. Assay Drug Dev Technol 12: 457–469.
149. Schwach V, Passier R (2016). Generation and purification of human stem cell-derived cardiomyocytes. Differentiation 91: 126–138.
150. Schwartz PJ, Woosley RL (2016). Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol 67: 1639–1650.
151. Shah RR (2005). Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead. Drug Saf 28: 1009–1028.
152. Siramshetty VB, Nickel J, Omieczynski C, Gohlke B-O, Drwal MN, Preissner R (2016). WITHDRAWN – a resource for withdrawn and discontinued drugs. Nucleic Acids Res 44: D1080–D1086.
153. Song L, Awari DW, Han EY, Uche-Anya E, Park S-HE, Yabe YA et al. (2015). Dual optical recordings for action potentials and calcium handling in induced pluripotent stem cell models of cardiac arrhythmias using genetically encoded fluorescent indicators. Stem Cells Transl Med 4: 468–475.
154. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
155. Spira ME, Hai A (2013). Multi-electrode array technologies for neuroscience and cardiology. Nat Nanotechnol 8: 83–94.
156. Stams TR, Oosterhoff P, Heijdel A, Dunnink A, Beekman JD, van der Nagel R et al. (2016). Beat-to-beat variability in preload unmasks latent risk of Torsade de Pointes in anesthetized chronic atrioventricular block dogs. Circ J 80: 1336–1345.
157. Stockbridge N, Zhang J, Garnett C, Malik M (2012). Practice and challenges of thorough QT studies. J Electrocardiol 45: 582–587.
158. Svanström H, Pasternak B, Hviid A (2014). Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ 349: g4930–g4930.
159. Tan HL, Bardai A, Shimizu W, Moss AJ, Schulze-Bahr E, Noda T et al. (2006). Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications. Circulation 114: 2096–2103.
160. Terrenoire C, Wang K, Tung KWC, Chung WK, Pass RH, Lu JT et al. (2013). Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol 141: 61–72.
161. Tirziu D, Giordano FJ, Simons M (2010). Cell communications in the heart. Circulation 122: 928–937.
162. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J (2007). The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8: 4–15.
163. Townsend C, Brown BS (2013). Predicting drug-induced QT prolongation and torsades de pointes: a review of preclinical endpoint measures. Curr Protoc Pharmacol Chapter 10: Unit 10.16.
164. Turnbull IC, Karakikes I, Serrao GW, Backeris P, Lee J-J, Xie C et al. (2014). Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J 28: 644–654.
165. Vaidyanathan R, Markandeya YS, Kamp TJ, Makielski JC, Janaury CT, Eckhardt LL (2016). IK1-enhanced human induced pluripotent stem cell-derived cardiomyocytes: an improved cardiomyocyte model to investigate inherited arrhythmia syndromes. Am J Physiol Heart Circ Physiol 310: H1611–H1621.
166. van den Berg CW, Elliott DA, Braam SR, Mummery CL, Davis RP (2016). Differentiation of human pluripotent stem cells to cardiomyocytes under defined conditions. Methods Mol Biol 1353: 163–180.
167. van der Heyden MAG, Jonsson MKB (2012). Personalized medicine and the role of induced pluripotent stem cells. Cardiovasc Res 95: 395–396.
168. Varga ZV, Ferdinandy P, Liaudet L, Pacher P (2015). Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 309: H1453–H1467.
169. Veerman CC, Kosmidis G, Mummery CL, Casini S, Verkerk AO, Bellin M (2015). Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? Stem Cells Dev 24: 1035–1052.
170. Vejpongsa P, Yeh ETH (2014). Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64: 938–945.
171. Viskin S, Havakuk O, Schwaber MJ (2015). Pro-arrhythmic effects of noncardiac medications: lessons from macrolide antibiotics. J Am Coll Cardiol 66: 2185–2188.
172. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM et al. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 14: 475–486.
173. Woosley RL, Romero K (2013). Assessing cardiovascular drug safety for clinical decision-making. Nat Rev Cardiol 10: 330–337.
174. Xi B, Wang T, Li N, Ouyang W, Zhang W, Wu J et al. (2011). Functional cardiotoxicity profiling and screening using the xCELLigence RTCA cardio system. J Lab Autom 16: 415–421.
175. Yu Z, IJzerman AP, Heitman LH (2015). Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors. Br J Pharmacol 172: 940–955.
176. Yu Z, Liu J, van Veldhoven JPD, Ijzerman AP, Schalij MJ, Pijnappels DA et al. (2016). Allosteric modulation of Kv11.1 (hERG) channels protects against drug-induced ventricular arrhythmias. Circ Arrhythm Electrophysiol 9: e003439.
177. Zhang H, Zou B, Yu H, Moretti A, Wang X, Yan W et al. (2012). Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci U S A 109: 11866–11871.
178. Zhang M, D'Aniello C, Verkerk AO, Wrobel E, Frank S, Ward-van Oostwaard D et al. (2014). Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci U S A 111: E5383–E5392.
179. Zhao M, Forrester JV, McCaig CD (1999). A small, physiological electric field orients cell division. Proc Natl Acad Sci U S A 96: 4942–4946.
180. Zhu R, Millrod MA, Zambidis ET, Tung L (2016). Variability of action potentials within and among cardiac cell clusters derived from human embryonic stem cells. Sci Rep 6: 18544.
181. Zimmermann WH, Schneiderbanger K (2002). Tissue engineering of a differentiated cardiac muscle construct. Circulation 90: 223–230.